Seladelpar is granted Breakthrough Therapy Designation for PBC by the FDA

[CathyPBC]

Seladelpar is a drug therapy under development by CymaBay Therapeutics in Newark. California for use in patients with Primary Biliary Cholangistis (PBC). This past week, CymaBay announced that the FDA had granted "Breakthrough Therapy Designation" for this drug.

You can read the official news release by clicking the link below:

ir.stockpr.com/cymabay/pres...

Cathy